GlassScriptPhysician profile
Irman Forghani
NPI 1427348549
$3,145.95
in general payments reported to CMS, 2019-2025
31 companies · $1,252 in 2025
The $1,252 reported for 2025 was more than what a typical Clinical Genetics (M.D.) provider received nationally (typical 2025 total: $255).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $45.00 · 2021: $449 · 2023: $506 · 2024: $894 · 2025: $1,252.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,652.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,652.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Genetic Laboratories, INC. | $609.54 | 2021-2024 | Prolaris, Myrisk |
| Genzyme Corporation | $310.29 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $294.84 | 2021-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Seagen INC. | $170.00 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $168.02 | 2024-2025 | Fruzaqla, Alunbrig, Ninlaro |
| Tempus Ai, INC | $135.05 | 2024-2025 | Xt Cdx |
| Daiichi Sankyo INC. | $127.50 | 2024-2025 | Enhertu |
| Abbvie INC. | $116.20 | 2021 | |
| Incyte Corporation | $112.44 | 2023-2025 | Jakafi, Monjuvi, Pemazyre |
| Adaptive Biotechnologies Corporation | $97.06 | 2024-2025 | Clonoseq |
| Intuitive Surgical, INC. | $93.69 | 2025 | |
| Genentech USA, INC. | $88.59 | 2024-2025 | Phesgo, Venclexta, Tecentriq |
| Pharmacosmos Therapeutics INC. | $83.38 | 2024-2025 | Monoferric, Cosela |
| Servier Pharmaceuticals LLC | $77.19 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $69.77 | 2024-2025 | Strensiq, Ultomiris |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biomarin Pharmaceutical INC. | $68.00 | 2021 | |
| Janssen Biotech, INC. | $66.85 | 2024 | Darzalex, Talvey, Tecvayli |
| Agios Pharmaceuticals, INC. | $66.41 | 2024-2025 | Pyrukynd |
| Aveo Pharmaceuticals, INC. | $62.19 | 2025 | |
| Eisai INC. | $51.79 | 2023-2025 | |
| Genmab U.S., INC. | $46.26 | 2024 | Epkinly |
| Pfizer INC. | $33.73 | 2024 | |
| Stemline Therapeutics INC. | $32.68 | 2025 | Orserdu |
| Ipsen Biopharmaceuticals, INC | $29.39 | 2025 | Onivyde |
| Sobi, INC | $23.70 | 2025 | |
| Sumitomo Pharma America, INC. | $23.36 | 2025 | Orgovyx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.73 | 2025 | |
| Beone Medicines USA, INC. | $19.09 | 2025 | Brukinsa |
| Astrazeneca Pharmaceuticals LP | $17.67 | 2024 | Imfinzi |
| Pharmaand Gmbh | $14.27 | 2025 | Rubraca |
| Tolmar, INC. | $14.27 | 2025 | Rubraca |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Irman Forghani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.